Zepbound (Tirzepatide) Administration Guidelines

Dosing Considerations

• The American Diabetes Association and other clinical guidelines support the use of a 7.5 mg dose as part of a dose escalation regimen for patients with type 2 diabetes or those using the medication for weight management 1
• No dosage adjustment is required for patients with renal impairment, including those with eGFR ≥20 mL/min per 1.73 m², according to the Mayo Clinic Proceedings 1
• For patients with severe renal impairment (eGFR <30 mL/min), careful monitoring is recommended due to potential delayed drug clearance, as suggested by the Mayo Clinic Proceedings 1